Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill directs the Secretary of Health and Human Services (HHS) to conduct or support research on increasing early detection of and intervention for uterine fibroids and to develop evidence-based strategies for use in health care settings. HHS may award grants to States to run programs that increase early detection and intervention, support public awareness campaigns, pay for screening procedures (including advanced gynecological imaging), provide patient navigation services, implement the HHS strategies, and facilitate access to care.
Scope and scale of federal involvement: liberals emphasize benefits of federal funding and equity focus; conservatives worry about federal spending and expansion of HHS authority.
Relative to its intended legislative type, this bill clearly establishes HHS authority to research uterine fibroid detection/intervention, to formulate strategies, to award State grants for implementation and related research, and to report to Congress.
This bill directs the Secretary of Health and Human Services (HHS) to conduct or support research on increasing early detection of and intervention for uterine fibroids and to develop evidence-based strategies for use in health care settings.
HHS may award grants to States to run programs that increase early detection and intervention, support public awareness campaigns, pay for screening procedures (including advanced gynecological imaging), provide patient navigation services, implement the HHS strategies, and facilitate access to care.
The Secretary may also award grants for research (including clinical trials) into disparities in pain control and management in fibroid surgical treatment and into Asherman’s Syndrome and other intrauterine conditions.
On content alone the bill is narrowly focused, technocratic, and addresses a non-ideological health need—factors that favor passage. Major hurdles are procedural and fiscal: the bill authorizes grant authority without specifying funding, so enactment would likely require appropriations or inclusion in a larger package. That dependence on separate funding negotiations reduces the standalone probability that the bill as written becomes law, while still leaving a moderate chance if folded into appropriations or an omnibus vehicle.
Relative to its intended legislative type, this bill clearly establishes HHS authority to research uterine fibroid detection/intervention, to formulate strategies, to award State grants for implementation and related research, and to report to Congress. However, it omits essential implementation and fiscal details typically expected for a grant-authorizing substantive statute.
Scope and scale of federal involvement: liberals emphasize benefits of federal funding and equity focus; conservatives worry about federal spending and expansion of HHS authority.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and scale of federal involvement: liberals emphasize benefits of federal funding and equity focus; conservatives worry about federal spending and expansion of HHS authority.
A mainstream liberal would likely view this bill positively as a targeted federal effort to address a common, often under-recognized women's health condition and its disparities.
They would focus on the bill’s support for research, funding for screening access (including payment for imaging), patient navigation, and explicit attention to disparities in pain management and intrauterine conditions.
They would see this as consistent with priorities to reduce health inequities and improve reproductive health care access.
A centrist/moderate is likely to view the bill as a reasonable, narrowly scoped federal initiative to improve an identifiable public health issue.
They will appreciate that the bill focuses on research, grants, and evidence-based strategies rather than mandates.
Their main interest will be in measurable outcomes, clear cost implications, and federal–state coordination.
A mainstream conservative will be cautiously skeptical but not uniformly opposed.
They may accept targeted, voluntary federal grants for research and state programs on a health condition, but will be concerned about open-ended federal spending, expansion of HHS authority, and potential federal intrusion into state healthcare decisions.
They will likely press for fiscal offsets, clear limits on federal obligations, and protections against federal mandates or regulatory overreach.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is narrowly focused, technocratic, and addresses a non-ideological health need—factors that favor passage. Major hurdles are procedural and fiscal: the bill authorizes grant authority without specifying funding, so enactment would likely require appropriations or inclusion in a larger package. That dependence on separate funding negotiations reduces the standalone probability that the bill as written becomes law, while still leaving a moderate chance if folded into appropriations or an omnibus vehicle.
The bill has not accumulated any surfaced votes yet.
Scope and scale of federal involvement: liberals emphasize benefits of federal funding and equity focus; conservatives worry about federal…
On content alone the bill is narrowly focused, technocratic, and addresses a non-ideological health need—factors that favor passage. Major…
Relative to its intended legislative type, this bill clearly establishes HHS authority to research uterine fibroid detection/intervention, to formulate strategies, to award State grants for implementation and related re…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.